Sana Biotechnology

Sana Biotechnology and Uppsala University Hospital announced a clinical trial for UP421, aiming to enable islet cell transplantation in type 1 diabetes patients without immunosuppression. The study focuses on safety, cell survival, immune evasion, and C-peptide production, potentially advancing treatments like SC451.

Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted into a type 1 diabetes patient survived, functioned, and evaded immune rejection without immunosuppression. C-peptide levels indicated insulin production, and MRI confirmed graft survival. The study suggests potential for scalable, curative treatments for type 1 diabetes.

Sana Biotechnology, Inc. reported initial results from a first-in-human study transplanting UP421, an allogeneic primary islet cell therapy with HIP technology, into a type 1 diabetes patient without immunosuppression. Results at four weeks showed pancreatic beta cell survival and function, indicated by C-peptide presence and increased levels with MMTT, alongside MRI evidence of graft survival. No safety issues were identified, and HIP-modified cells evaded immune responses, demonstrating potential to overcome immunologic and autoimmune rejection without immunosuppression.

Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted into a type 1 diabetes patient evade immune rejection and produce insulin without immunosuppression. C-peptide levels indicate insulin production, and MRI confirms graft survival. The study, conducted with Uppsala University Hospital, marks a significant step towards a scalable, curative treatment for type 1 diabetes.

Sana Biotechnology's shares surged 150% after preliminary results from a clinical study on UP421, an engineered islet cell therapy for type 1 diabetes, showed promising outcomes without immunosuppressive drugs, indicating successful cell survival and function.

Sana Biotechnology's UP421, an allogeneic primary islet cell therapy using hypoimmune technology, was successfully transplanted into a type 1 diabetes patient without immunosuppression. Results showed pancreatic beta cell survival and function, evidenced by C-peptide presence and increased levels post-meal, with no safety issues. MRI confirmed graft survival, indicating evasion of immune responses.

Sana Biotechnology achieved a breakthrough in treating type 1 diabetes (T1D) by successfully implanting immune-evading islets from deceased donors into a patient, enabling insulin production without immunosuppression. This advancement paves the way for scalable stem cell-based therapies, offering hope for a broader T1D cure.

Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted into a type 1 diabetes patient evade immune rejection and produce insulin without immunosuppression. Results include detectable C-peptide levels, indicating insulin production, and MRI evidence of graft survival. The study highlights potential for a scalable, curative treatment for type 1 diabetes.

Sana Biotechnology's first-in-human study shows HIP-engineered islet cells transplanted without immunosuppression in a type 1 diabetes patient survived, functioned, and evaded immune detection, evidenced by C-peptide levels and MRI. This breakthrough suggests a potential scalable, curative treatment for type 1 diabetes without immunosuppression.